STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Biotechnology

Study Highlights the Life-Saving Potential of Obesity Drugs and Strengthens the Bullish Case for Viking Therapeutics

byLuca Blaumann
October 17, 2024
in Biotechnology, Mid-Cap
Reading Time: 4 mins read
Share on TwitterShare on LinkedIn

VKTX’s Innovative Drug Candidates Could Unlock Significant Value for Patients and Investors

A recent study has shone new light on the life-saving potential of GLP-1-based obesity drugs, further solidifying the bullish outlook for Viking Therapeutics (VKTX). As the battle against obesity intensifies, new therapies are increasingly viewed as crucial tools in reducing obesity-related deaths. Despite these benefits, the accessibility of these drugs remains limited due to financial barriers and restrictive insurance coverage. This gap in access represents a significant issue, but for companies like Viking Therapeutics, it also offers an opportunity to make a substantial impact on public health and generate meaningful shareholder value.

The study underscores the importance of expanding access to obesity drugs such as GLP-1 agonists, which can significantly improve survival rates among patients with obesity. Viking Therapeutics’ promising drug candidate VK2735, with both oral and subcutaneous (subQ) delivery options, is well-positioned to address these needs and potentially redefine how obesity treatments are accessed and administered. With upcoming data releases and pivotal trials on the horizon, VKTX is emerging as a key player in the fight against obesity.

Obesity: A Public Health Crisis

Obesity is a major public health issue in the U.S., affecting over 40% of the population and contributing to a host of related diseases such as diabetes, cardiovascular disease, and certain cancers. Despite its significant impact on health and mortality, obesity is often under-recognized as a direct cause of death. The new study reveals that expanding access to GLP-1-based obesity drugs could save thousands of lives annually. However, access remains unequal, with patients on private insurance more likely to benefit from these drugs than those on Medicare or without insurance.

The study suggests that with current access levels, approximately 6,000 deaths could be prevented annually, mostly among privately insured patients. By improving access, as many as 10,000 additional lives could be saved among Medicare beneficiaries, and 3,000 among uninsured patients. This stark disparity highlights the need for expanded drug coverage and increased availability of these life-saving treatments.

VK2735: A Promising Candidate in the Fight Against Obesity

Viking Therapeutics is making significant strides with its GLP-1 drug candidate, VK2735. The company is developing both oral and subQ versions of the drug, offering flexibility and broader access to patients who may have difficulty affording or obtaining these medications through traditional channels.

In a recent Phase 1 study, VK2735 demonstrated impressive results. Patients who took the oral form of the drug experienced a dose-dependent reduction in body weight over a 28-day period, with the highest dose group achieving a 5.3% reduction in weight compared to a 2.1% reduction in the placebo group. Notably, the drug exhibited a favorable safety profile, with most adverse events limited to mild nausea and no vomiting, making it a promising option for wider use.

The company is continuing to explore higher doses of VK2735, with additional data expected to be unveiled at the upcoming ObesityWeek conference on November 3rd. These results could further bolster the case for VK2735 as a best-in-class obesity treatment, unlocking significant value for patients and shareholders alike.

The Case for Over-the-Counter Access

Viking Therapeutics’ innovation in GLP-1 therapy doesn’t stop with prescription options. A survey conducted among primary care physicians (PCPs) revealed that approximately 50% of respondents would support the availability of an oral obesity agent over-the-counter (OTC). This would be a game-changer, making obesity treatments far more accessible to a broader population, particularly those facing financial barriers.

The OTC potential for VK2735 is an exciting prospect that could attract partnerships with larger pharmaceutical companies, seeking to capitalize on this opportunity. Expanding access through OTC availability would not only improve patient outcomes but also extend the product’s life cycle, providing long-term value for VKTX.

Upcoming Catalysts and Investment Potential

Viking Therapeutics’ lead candidate, VK2809, a THR-β agonist for non-alcoholic steatohepatitis (NASH), continues to show promise as well. The company’s upcoming catalysts include additional data from VK2735 in the second half of 2024 and the initiation of a Phase 2 study. Moreover, the outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for VK2809 in NASH could pave the way for continued development into Phase 3, further boosting VKTX’s potential valuation.

With a combination of promising drug candidates, upcoming clinical milestones, and a favorable market landscape, Viking Therapeutics presents a compelling investment opportunity. The company’s innovative approach to obesity and NASH treatments could unlock significant value not only for patients in need but also for investors seeking upside in a growing therapeutic market.

You might like this article:Here are the Nuclear Stocks You Need To Watch After Amazon’s Nuclear Investment

Tags: analystBreakingGrowthMoversNewsStock Market
Previous Post

Here are the Nuclear Stocks You Need To Watch After Amazon’s Nuclear Investment

Next Post

Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Related Posts

bitcoin-1

KULR Technology Secures $20 Million Bitcoin-Backed Credit Facility from Coinbase

byLuca Blaumann
July 8, 2025
0

New financing provides non-dilutive capital to support KULR’s strategic Bitcoin accumulation plans KULR Technology Group (KULR) announced Monday that it...

Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

byLuca Blaumann
July 7, 2025
0

Following a 38-to-1 stock split and explosive rally, the biotech firm's volatile trading persists despite a multi-year loss streak Regencell...

Shake Shack Sizzles as Analysts Raise Price Targets on Growth and Leadership Optimism

byLuca Blaumann
June 26, 2025
0

Shares climb nearly 6% in 2025 as Barclays and Oppenheimer praise new strategy and expansion plans Shake Shack (SHAK) is...

Next Post

Ulta Beauty: Long-Term Prospects Shine Amidst Industry Challenges

Latest News

Trump Executive Order Deals Blow to U.S. Solar Sector

IBM Launches Power11 Chips to Boost AI Efficiency and Data Center Reliability

KULR Technology Secures $20 Million Bitcoin-Backed Credit Facility from Coinbase

Citi Boosts Nvidia Target on Soaring Global AI Demand

Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

Based on Your Interest

Cybersecurity

CrowdStrike Hits Record High After Wedbush Declares It Cybersecurity’s “Gold Standard”

July 3, 2025
Large-Cap

OpenAI Secures 4.5 GW of Data Center Power From Oracle in Record-Breaking Deal

July 3, 2025
Large-Cap

Footwear Stocks Rise After Trump Announces Vietnam Trade Deal

July 2, 2025

Recommended

Altcoins

Circle Applies for U.S. Trust Bank Charter to Strengthen Stablecoin Strategy

July 1, 2025
Asset Management

Robinhood Launches Tokenized Stocks in EU, Expands Crypto Offerings Globally

June 30, 2025
Altcoins

BitMine Raises $250 Million to Launch One of the Largest Public Ether Treasuries

June 30, 2025
IT Services

Oracle Secures Massive $30 Billion Cloud Deal, Signaling Major Market Expansion

June 30, 2025
Blog

EXCLUSIVE: MIRA Pharmaceuticals’ Disruptive Path In Neurology And Metabolic Disorders

June 30, 2025
Stoxpo

Follow us on social media:

Highlights

  • Trump Executive Order Deals Blow to U.S. Solar Sector
  • IBM Launches Power11 Chips to Boost AI Efficiency and Data Center Reliability
  • KULR Technology Secures $20 Million Bitcoin-Backed Credit Facility from Coinbase
  • Citi Boosts Nvidia Target on Soaring Global AI Demand
  • Regencell Bioscience’s Stock Whipsaws Again Amid 17,000% Surge in 2025

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

solar-panels

Trump Executive Order Deals Blow to U.S. Solar Sector

July 8, 2025
trading-chart

IBM Launches Power11 Chips to Boost AI Efficiency and Data Center Reliability

July 8, 2025
bitcoin-1

KULR Technology Secures $20 Million Bitcoin-Backed Credit Facility from Coinbase

July 8, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?